DK3127917T3 - Fremgangsmåde til fremstilling af antistof gennem regulering af sukkerindhold i antistof - Google Patents

Fremgangsmåde til fremstilling af antistof gennem regulering af sukkerindhold i antistof Download PDF

Info

Publication number
DK3127917T3
DK3127917T3 DK15773537.4T DK15773537T DK3127917T3 DK 3127917 T3 DK3127917 T3 DK 3127917T3 DK 15773537 T DK15773537 T DK 15773537T DK 3127917 T3 DK3127917 T3 DK 3127917T3
Authority
DK
Denmark
Prior art keywords
antibody
regulating
procedure
production
sugar content
Prior art date
Application number
DK15773537.4T
Other languages
English (en)
Inventor
Jae Young Chang
Eun Ho Hwang
Yong Jin Kim
Won Kyum Kim
Sang Kyung Park
Jun Yong Park
Kyo Eun Ahn
Yong Ho Ahn
Ji Yong Yoon
Jung Woo Lee
Original Assignee
Prestige Biopharma Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prestige Biopharma Pte Ltd filed Critical Prestige Biopharma Pte Ltd
Application granted granted Critical
Publication of DK3127917T3 publication Critical patent/DK3127917T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/005Glycopeptides, glycoproteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DK15773537.4T 2014-04-02 2015-04-02 Fremgangsmåde til fremstilling af antistof gennem regulering af sukkerindhold i antistof DK3127917T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020140039307A KR101660580B1 (ko) 2014-04-02 2014-04-02 항체의 당 함량 조절을 통한 항체의 제조 방법
PCT/KR2015/003310 WO2015152658A1 (ko) 2014-04-02 2015-04-02 항체의 당 함량 조절을 통한 항체의 제조 방법

Publications (1)

Publication Number Publication Date
DK3127917T3 true DK3127917T3 (da) 2021-09-20

Family

ID=54240880

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15773537.4T DK3127917T3 (da) 2014-04-02 2015-04-02 Fremgangsmåde til fremstilling af antistof gennem regulering af sukkerindhold i antistof

Country Status (9)

Country Link
US (1) US10808272B2 (da)
EP (1) EP3127917B1 (da)
JP (1) JP6389530B2 (da)
KR (1) KR101660580B1 (da)
CN (1) CN106459185B (da)
DK (1) DK3127917T3 (da)
ES (1) ES2893536T3 (da)
PT (1) PT3127917T (da)
WO (1) WO2015152658A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI734775B (zh) 2016-04-26 2021-08-01 美商美國泰福生技股份有限公司 細胞培養基
AU2019379858B2 (en) * 2018-11-13 2024-01-04 Janssen Biotech, Inc. Control of trace metals during production of anti-CD38 antibodies
CN111321188B (zh) * 2018-12-17 2024-10-29 嘉和生物药业有限公司 一种抗体糖型改造的配方、细胞培养方法以及在工业化生产中的应用
JP7635137B2 (ja) 2019-03-14 2025-02-25 ヤンセン バイオテツク,インコーポレーテツド 抗tnf抗体組成物を産生するための方法
CN113840837A (zh) * 2019-03-14 2021-12-24 詹森生物科技公司 用于产生抗tnf抗体组合物的方法
CN114990049B (zh) * 2022-04-26 2024-01-16 鼎康(武汉)生物医药有限公司 一种同时调节细胞表达产物的糖型和电荷异质性的方法
CN116590371B (zh) * 2023-07-13 2023-10-17 智享生物(苏州)有限公司 一种降低中华仓鼠卵巢细胞中抗体高甘露糖型的细胞培养方法
WO2025137086A1 (en) * 2023-12-20 2025-06-26 Genentech, Inc. Reducing alpha-gal

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08336389A (ja) * 1995-06-14 1996-12-24 Mitsui Toatsu Chem Inc 糖蛋白質の糖鎖構造を制御する方法
PT1176195E (pt) * 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
DE60120356T2 (de) * 2000-02-08 2007-06-14 Genentech, Inc., South San Francisco Verbesserte galactosylierung von rekombinanten proteinen
EP1417577A4 (en) 2001-08-14 2009-08-26 Verisity Design Inc SYSTEM AND METHOD FOR VCD ON DEMAND
US7439043B2 (en) * 2001-10-10 2008-10-21 Neose Technologies, Inc. Galactosyl nucleotide sugars
WO2005070962A1 (en) 2004-01-21 2005-08-04 Novozymes A/S Production of a monoclonal antibody in a heterokaryon fungus or in a fungal host cell
CN1918179A (zh) * 2004-01-21 2007-02-21 诺和酶股份有限公司 在异核体真菌或真菌宿主细胞中产生单克隆抗体
AU2011205185B2 (en) * 2004-04-15 2013-05-09 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
ATE536373T1 (de) * 2005-10-21 2011-12-15 Genzyme Corp Therapiemittel auf antikörperbasis mit erhöhter adcc-aktivität
SI1957630T2 (sl) * 2005-12-08 2023-07-31 Amgen Inc. Izboljšana proizvodnja glikoproteinov z uporabo mangana
CA2677179C (en) * 2007-01-31 2016-02-16 Dow Global Technologies Inc. Bacterial leader sequences for increased expression
NZ596283A (en) * 2009-05-11 2013-08-30 Pfenex Inc Production of recombinant proteins utilizing non-antibiotic selection methods and the incorporation of non-natural amino acids therein
RU2604811C2 (ru) 2010-05-27 2016-12-10 Мерк Шарп Энд Домэ Корп. Способ получения антител с улучшенными свойствами
EP2678030A4 (en) * 2011-02-25 2015-02-18 Merck Sharp & Dohme PREPARATION OF N- AND O-SIALYLATED TNFRII-FC FUSION PROTEINS IN YEAST
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
KR20130057959A (ko) * 2011-11-24 2013-06-03 한화케미칼 주식회사 항 her2 단일클론항체와 il-2를 포함하는 융합 단일클론 항체 및 이를 포함하는 암치료용 조성물
EP2809773B1 (en) * 2012-01-30 2020-09-02 Dr. Reddy's Laboratories Limited Process of modulating man5 and/or afucosylation content of glycoprotein composition
KR101318498B1 (ko) * 2012-03-08 2013-10-16 한화케미칼 주식회사 재조합 단백질의 생산성 향상을 위한 배양용 배지 첨가용 조성물
CN103320388B (zh) * 2012-03-20 2015-10-28 无锡药明康德生物技术股份有限公司 提高抗体表达量和改良糖基化水平的细胞培养方法

Also Published As

Publication number Publication date
US20170107551A1 (en) 2017-04-20
CN106459185A (zh) 2017-02-22
JP6389530B2 (ja) 2018-09-12
EP3127917B1 (en) 2021-09-01
JP2017511137A (ja) 2017-04-20
ES2893536T3 (es) 2022-02-09
KR101660580B1 (ko) 2016-09-28
KR20150115066A (ko) 2015-10-14
US10808272B2 (en) 2020-10-20
EP3127917A4 (en) 2017-04-26
WO2015152658A1 (ko) 2015-10-08
EP3127917A1 (en) 2017-02-08
PT3127917T (pt) 2021-10-15
CN106459185B (zh) 2021-05-07

Similar Documents

Publication Publication Date Title
DK3556775T3 (da) Anti-lag-3 antistoffer til behandling af hæmatologiske maligniteter
IL251963A0 (en) Anti-pd-1 antibodies
DK3140393T3 (da) Fremstillingsmetode for voksne leverstamceller
LT3126395T (lt) Daugiaspecifiniai antikūnai
DK3183272T3 (da) Asymmetriske multispecifikke antistoffer
EP3356420C0 (en) MULTI-SPECIFIC ANTIBODIES
LT3161007T (lt) Multispecifiniai antikūno konstruktai
DK3192902T3 (da) Fremgangsmåde til fremstilling af graphenholdige viscosefibre
HUE053857T2 (hu) Anti-GITR antitestek és eljárások azok elõállítására
DK3492632T3 (da) Metoder til behandling af lithiumholdige materialer
DK3191517T3 (da) Krydsreaktive siglec-antistoffer
DK3164414T3 (da) Antistoffer for IL-15
DK3253453T3 (da) Fremgangsmåde til fremstilling af mælk med højt indbygget vitamin D3-indhold
DK3237432T3 (da) Proteinfremstilling
DK3215517T3 (da) Ether-funktionaliseret lignin til brændstofsproduktion
DK3166904T3 (da) Fremgangsmåde til fremstilling af betonelementer
DK3218396T3 (da) Fremgangsmåde til fremstilling af højaffinitets antistoffer
DK3160266T3 (da) Sukkererstatningssammensætning
DK3147369T3 (da) Fremgangsmåde til produktion af fibroinlignende protein
HUE049170T2 (hu) Eljárás szubsztituált cikloszerinek elõállítására
PT3127917T (pt) Método para preparar anticorpo através da regulação do conteúdo de açúcar do anticorpo
DK3138903T3 (da) Celler til produktion af humant antistof
HUE047455T2 (hu) HPA-1A elleni antitestek
LT3178931T (lt) Anti-orai1 antikūnas
EP3160502B1 (en) BI-SPECIFIC ANTIBODIES ANTI-IL4-IL13